North Carolina State University researchers reported RuPHOTACs, a red-light–activatable platform that keeps PROTAC-like protein degraders inactive until exposure to specific light conditions. The approach uses a ruthenium-based molecular cage to prevent premature target engagement, aiming to improve spatial control and reduce off-target degradation in healthy tissues. Published in Nature Communications, the proof-of-concept suggests a path for controllable degradation therapies, particularly in settings where target proteins are also present outside diseased tissue and conventional PROTAC exposure risks collateral biology.